Literature DB >> 18699979

Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study.

Brian I Carr1, Shama C Buch, Venkateswarlu Kondragunta, Petr Pancoska, Robert A Branch.   

Abstract

BACKGROUND AND AIMS: A total of 967 patients with unresectable and untransplantable, biopsy-proven hepatocellular carcinoma (HCC) were prospectively evaluated at baseline and followed up till death.
METHODS: Survival was the end-point for all analyses.
RESULTS: We found in our overall analysis, that male gender, ascites, cirrhosis, portal vein thrombosis (PVT), elevated alpha-fetoprotein (AFP) or bilirubin or alkaline phosphatases were each statistically significant adverse prognostic factors. Patients with normal AFP survived longer than those with elevated AFP, in the presence of PVT, large or bilobar tumors or cirrhosis. We used a bivariate analysis to separate patient subgroups based on poor liver function and aggressive tumor characteristics. In subgroup analysis based on these subsets, there was clear discrimination in survival between subsets; in addition both cirrhosis and presence of PVT were significant, independent but modest risk factors. The results of this large dataset show that amongst nonsurgical HCC patients, there are clear subsets with longer survival than other subsets.
CONCLUSIONS: This data also supports the concept of heterogeneity of HCC.

Entities:  

Mesh:

Year:  2008        PMID: 18699979     DOI: 10.1111/j.1440-1746.2008.05487.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  18 in total

1.  Small HCCs identified by screening.

Authors:  Petr Pancoska; Massimo De Giorgio; Stefano Fagiuoli; Brian I Carr
Journal:  Dig Dis Sci       Date:  2011-04-05       Impact factor: 3.199

Review 2.  Portal vein thrombosis.

Authors:  Yogesh K Chawla; Vijay Bodh
Journal:  J Clin Exp Hepatol       Date:  2015-01-06

3.  Portal vein thrombosis and liver transplant survival benefit.

Authors:  Michael J Englesbe; Douglas E Schaubel; Shijie Cai; Mary K Guidinger; Robert M Merion
Journal:  Liver Transpl       Date:  2010-08       Impact factor: 5.799

4.  HCC in older patients.

Authors:  Brian I Carr; Petr Pancoska; Robert A Branch
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

5.  Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype.

Authors:  Brian I Carr; Vito Guerra; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Semin Oncol       Date:  2014-03-06       Impact factor: 4.929

6.  Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.

Authors:  Xiang Da Dong; Brian I Carr
Journal:  Med Oncol       Date:  2010-11-24       Impact factor: 3.064

7.  Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.

Authors:  Brian I Carr; Venkateswarlu Kondragunta; Shama C Buch; Robert A Branch
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

8.  Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China.

Authors:  Ming Shi; Ji-An Chen; Xiao-Jun Lin; Rong-Ping Guo; Yun-Fei Yuan; Min-Shan Chen; Ya-Qi Zhang; Jin-Qing Li
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

9.  Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy.

Authors:  Weihu Wang; Xiaoli Feng; Tao Zhang; Jing Jin; Shulian Wang; Yueping Liu; Yongwen Song; Xinfan Liu; Zihao Yu; Yexiong Li
Journal:  Radiat Oncol       Date:  2010-08-23       Impact factor: 3.481

10.  Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation.

Authors:  Jian He; Zhao-Chong Zeng; Jia Fan; Jian Zhou; Jing Sun; Bing Chen; Ping Yang; Bin-Liang Wang; Bo-Heng Zhang; Jian-Ying Zhang
Journal:  BMC Cancer       Date:  2011-11-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.